- Home
- LILAK vs ANAB Comparison
LILAK vs ANAB Comparison
Compare LILAK & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILAK | ANAB |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | LILAK | ANAB |
|---|---|---|
| Price | $7.71 | $47.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $8.20 | ★ $60.18 |
| AVG Volume (30 Days) | ★ 944.0K | 482.0K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,433,000,000.00 | $169,467,000.00 |
| Revenue This Year | $1.37 | $135.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $4.23 | $12.21 |
| 52 Week High | $9.13 | $52.47 |
Technical Indicators
Market Signals| Indicator | LILAK | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 54.75 |
| Support Level | $7.34 | $44.25 |
| Resistance Level | $8.11 | $48.53 |
| Average True Range (ATR) | 0.28 | 2.96 |
| MACD | 0.10 | -0.20 |
| Stochastic Oscillator | 69.81 | 66.35 |
Price Performance
Historical ComparisonAbout LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).